血管疾病患者信息页面：直接口服抗凝剂 - 2020年更新 - Suppr | 超能文献

Vascular Disease Patient Information Page: Direct oral anticoagulants - 2020 update.

作者信息

Vazquez Sara R

机构信息

University of Utah Health Thrombosis Center, Salt Lake City, UT, USA.

出版信息

Vasc Med. 2020 Apr;25(2):196-199. doi: 10.1177/1358863X19898262. Epub 2020 Feb 7.

DOI:10.1177/1358863X19898262

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Vascular Disease Patient Information Page: Direct oral anticoagulants - 2020 update.血管疾病患者信息页面：直接口服抗凝剂 - 2020年更新

Vasc Med. 2020 Apr;25(2):196-199. doi: 10.1177/1358863X19898262. Epub 2020 Feb 7.

2

Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.肥胖患者直接口服抗凝剂的应用：国际血栓与止血学会科学与标准化委员会的指南

J Thromb Haemost. 2016 Jun;14(6):1308-13. doi: 10.1111/jth.13323. Epub 2016 Apr 27.

3

Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula.管理良好的华法林的安全性和有效性。来自瑞典耳廓质量登记处的一份报告。

Thromb Haemost. 2015 Jun;113(6):1370-7. doi: 10.1160/TH14-10-0859. Epub 2015 Feb 26.

4

Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.直接口服抗凝剂和华法林治疗心房颤动患者的处方模式和结局：真实世界分析。

J Cardiovasc Pharmacol Ther. 2019 Sep;24(5):428-434. doi: 10.1177/1074248419841634. Epub 2019 Apr 29.

5

Edoxaban in venous thromboembolism and stroke prevention: an appraisal.依度沙班用于静脉血栓栓塞症及预防卒中：一项评估

Vasc Health Risk Manag. 2016 Feb 29;12:45-51. doi: 10.2147/VHRM.S81569. eCollection 2016.

6

Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.达比加群与醋硝香豆素在“真实世界”房颤患者中的有效性和安全性比较

Europace. 2016 Sep;18(9):1319-27. doi: 10.1093/europace/euv397. Epub 2016 Feb 3.

7

Direct Oral Anticoagulants in Octogenarians With Atrial Fibrillation: It Is Never Too Late.直接口服抗凝剂在 80 岁以上的房颤患者中的应用：永远不会太晚。

J Cardiovasc Pharmacol. 2019 Apr;73(4):207-214. doi: 10.1097/FJC.0000000000000661.

8

Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation.性别对房颤患者口服抗凝治疗结局的影响。

J Am Coll Cardiol. 2018 Jul 17;72(3):271-282. doi: 10.1016/j.jacc.2018.04.066. Epub 2018 Jul 9.

9

State of play and future direction with NOACs: An expert consensus.NOACs 的现状和未来方向：专家共识。

Vascul Pharmacol. 2018 Jul;106:9-21. doi: 10.1016/j.vph.2018.04.001. Epub 2018 Apr 12.

10

Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran.新型口服抗凝剂的有效性、耐受性和安全性的真实数据：聚焦达比加群

High Blood Press Cardiovasc Prev. 2016 Jun;23(2):115-22. doi: 10.1007/s40292-016-0150-7. Epub 2016 May 20.

引用本文的文献

1

Vascular Disease Patient Information Page: Livedoid vasculopathy.血管疾病患者信息页面：类紫癜性血管病

Vasc Med. 2022 Dec;27(6):609-612. doi: 10.1177/1358863X221128620. Epub 2022 Oct 26.